Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166618 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
A NA study, sponsored by Allergan.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03166618: Clinical Trial NA study, sponsored by Allergan.
NCT03166618 is a NA study that was terminated before completion, run by Allergan. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03166618, a NA study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in adult participants seeking correction of temple hollowing.
Primary Outcome
The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.
Interventions
- DEVICE Juvéderm® VOLUMA XC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2017-07-21 |
| Phase | NA |
Why NCT03166618 stopped before completion
NCT03166618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Juvéderm® VOLUMA XC is the first listed.
NCT03166618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03166618 about?
NCT03166618 is a clinical study titled "Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing". This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in adult participants seeking correction of temple hollowing.
What is the current status of trial NCT03166618?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2017-04-24. Estimated completion is 2017-07-21.
What interventions are being tested in trial NCT03166618?
The interventions under investigation include: Juvéderm® VOLUMA XC (DEVICE).
Who is sponsoring clinical trial NCT03166618?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03166618's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI